PROTID under Global Health EDCTP3

21-11-2025

PROTID, the first phase 3 RCT examining TB prevention among people with TB with ancillary studies on screening, diagnosis, quality of care and cost- and epidemiological impact, was started in 2019, as part of the EDCTP2 programme supported by the European Union. Due to the COVID-19 pandemic, PROTID suffered significant delays. But as part of the Global Health EDCTP3 (co-funded by the EU) under the EU Horizon program, PROTID will be able to be completed.

 

The objective of this second chapter is to complete follow-up of the trial, thereby defining the best algorithm for investigation of TB infection and disease in people with diabetes, establishing safety and efficacy of TB preventive therapy and establish population impact and cost-utility of TB preventive therapy for people with diabetes. In addition, it will define and asses quality of care for people with combined diabetes and TB, and initiate quality improvement in care.